Menu
← Oncology Approval Tracker
FDA DECISION ·
Blenrep
belantamab mafodotin-blmf · GlaxoSmithKline
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory multiple myeloma after at least four prior therapies, including an anti-CD38 antibody, a proteasome inhibitor and an immunomodulatory agent.
LAMPGEN ANALYSIS
Why it matters
Introduced a BCMA-targeted antibody-drug conjugate under accelerated approval; this original monotherapy indication was later withdrawn.
What research teams should watch
Coordinate eye examinations and distinguish this historical indication from later, separately approved regimens.
PRIMARY RECORDS